Logo

California Licenses PGXL for Testing Services

Apr 21, 2014 | staff reporter

NEW YORK (GenomeWeb) – PGXL Laboratories has received licensure from California to provide its testing services in the state.

As a result, the Louisville, Ky.-based company can offer its testing services in all 50 states in the US, it said. According to PGXL's website, it provides pharmacogenetic tests for CYP2C19, CYP2D6, Factor V Leiden, Factor II, and others. It also offers molecular oncology testing for the detection of EGFR, HER2/neu (fluorescent in situ hybridization), JAK2, ALK (FISH), and other genes.

PGXL operates as a commercial and research lab and said that in 2001 it was the first laboratory CLIA-certified specifically to offer pharmacogenetic tests.

Filed under

Diagnostics
Molecular Diagnostics
PGXL Laboratories
Breaking News
The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.